

Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells

Tsvee Lapidot and Isabelle Petit

Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

Mobilization of hematopoietic stem and progenitor cells from the bone marrow into the circulation by repetitive, daily stimulations with G-CSF alone, or in combination with cyclophosphamide, is increasingly used clinically; however, the mechanism is not fully understood. Moreover, following mobilization stem cells also home back to the bone marrow, suggesting that stem cell release/mobilization and homing are sequential events with physiological roles. Previously, a role for cytokines such as G-CSF and SCF, and adhesion molecules such as VLA-4 and P/E selectins, was determined for stem cell mobilization. Recent results using experimental animal models and samples from clinical mobilization protocols demonstrate major involvement of chemokines such as stromal derived factor-1 (SDF-1) and IL-8, as well as proteolytic enzymes such as elastase, cathepsin G, and various MMPs in the mobilization process. These results will be reviewed together with the central roles of SDF-1 and CXCR4 interactions in G-CSF or G-CSF in combination with cyclophosphamide-induced mobilization. Furthermore, the central role of this chemokine in stem cell homing to the bone marrow as well as retention of undifferentiated cells within this tissue will also be discussed. © 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.

Definitive, repopulating stem cells

During embryonic development, blood-forming stem cells migrate from the fetal liver via the blood circulation, home to the bone marrow (BM), and repopulate this tissue with high levels of immature and maturing blood cells of all lineages, which in turn are released into the circulation while maintaining a small pool of undifferentiated stem cells within the bone marrow [1]. Prior to their localization in the murine fetal liver, hematopoietic stem cells can be isolated from the yolk sac and aorta-gonad-mesonephros (AGM) region even before completion of the circulatory system [2]. The vast majority of these stem cells, however, are not definitive stem cells (i.e., cannot migrate in the circulation and home to and repopulate the host bone marrow in order to rescue lethally irradiated recipients), since they require an additional maturation step in the form of *in vitro* incubation with stromal cells and cytokines before they develop from predefinitive into definitive (i.e., functional migrating and repopulating) stem cells [3–5]. Despite their inability to home to the BM, stem cells isolated from the murine yolk sac can give rise to

hematopoietic progeny if they are directly injected into the liver of newborn mice that were preconditioned as fetuses with low-dose chemotherapy [6]. These results demonstrate that stem cell motility (i.e., migration, homing, retention, and release) is crucial for hematopoietic development and bone marrow repopulation.

Circulating stem cells in peripheral blood

Immediately after birth, human umbilical cord blood (CB) cells contain relatively high levels of immature CD34⁺ progenitor cells (~0.5%), including a minority of more primitive, undifferentiated CD34⁺/CD38^{-/low} cells, suggesting high levels of hematopoietic stem cell migration via the circulation during late-stage embryonic development [7]. A small pool of hematopoietic stem cells within the bone marrow continuously produces high levels of immature and maturing myeloid and lymphoid blood cells with a limited lifespan, which are released into the circulation, while maintaining undifferentiated stem cells within the bone marrow throughout life [1]. However, very low levels of noncycling quiescent progenitor cells, including primitive stem cells, are also released into the peripheral blood. The physiological role of circulating stem cells, their turnover rate, their destination, and their fate are currently unknown. It is, however, believed that the physiological role of circu-

Offprint requests to: Tsvee Lapidot Ph.D., Dept. of Immunology, The Weizmann Institute, Rehovot 76100, Israel; E-mail: Tsvee.Lapidot@weizmann.ac.il

lating stem cells is to repopulate areas of damaged bone marrow and possibly also to continuously repopulate the thymus [1,8]. Alternatively, the possibility that circulating stem cells do not have a physiological role but may instead reflect a leakage of the system (i.e., that the mechanisms that restrict stem cells to the bone marrow are not perfect) also needs to be considered. Recently, Weissman et al. elegantly demonstrated that immature murine progenitor cells isolated from the circulation of donor mice are cleared very quickly, within a few minutes, from the circulation of intravenously transplanted congenic recipients. In addition, by pairing congenic mice and creating parabiotic mice with shared blood circulations, this study further revealed that hematopoietic stem cells rapidly and constitutively migrate through the circulation and suggest that they play a physiological role, i.e., the functional reengraftment of unconditioned bone marrow [9]. However, inflammation and trauma as a result of the surgery and the nonphysiological parabiotic joining of the mice may well result in enhanced levels of circulating stem cells, particularly given the wide range of stimuli that have previously shown to elicit stem cell release [10]. These results demonstrate that release of stem cells into the circulation and their homing back to the bone marrow are sequential events that could also be important in steady-state homeostatic processes. Thus, the concept of stem cell niches occupied by quiescent, undifferentiated cells in the bone marrow which are stationary may be an oversimplification of a more dynamic situation in which there is a higher migratory turnover of stem cells involving their release, migration in the circulation, homing, and reengraftment of the bone marrow as part of their developmental program (i.e., proliferation and differentiation). Moreover, we suggest that in addition to hematopoietic osteoclasts, which continuously destruct the bone surface by forming absorption pits and stromal osteoblasts that remodel new bone formation, there are other vital players in the bone marrow destruction/restructure cycle. These include different types of hematopoietic and stromal cells within the bone marrow that secrete a wide array of proteolytic enzymes in response to stimulation with cytokines or chemokines. These proteolytic enzymes degrade and cleave the bone marrow extracellular matrix, adhesion molecules, cytokines, and chemokines and also facilitate transendothelium cell migration [11]. These processes could also mediate stem cell release and remodeling of the bone marrow microenvironment, followed by stem cell migration via the circulation, homing back to the bone marrow, and repopulation of damaged/restructured sites in this organ as part of the continuous replenishment of the blood with new immature and maturing cells while maintaining undifferentiated stem cells. In support of our hypothesis, by applying cDNA array technology two recent studies reveal high expression of proteinase 3 and low expression of a proteinase 3 inhibitor in human bone marrow CD34⁺ cells compared to mobilized CD34⁺ cells isolated from healthy donors treated with

granulocyte colony-stimulating factor (G-CSF). These results suggest that the ability to cleave connective tissue by proteinase 3 in the bone marrow is needed for maintaining a niche for hematopoietic progenitors [12,13]. Interestingly, G-CSF stimulation induces both stem cell mobilization and osteoclast-mediated bone resorption and calcium release. In addition, soluble calcium causes detachment of immature progenitor cells from fibronectin [14]. Since osteoclasts are derived from hematopoietic stem cells and since immature osteoblasts lining the endosteum region secrete cytokines and chemokines and are in proximity to hematopoietic stem and progenitor cell niches, external and internal bone and bone marrow destruction followed by remodeling could be orchestrated. These processes could be sequential events that regulate new bone formation as well as stem cell self-renewal and steady-state hematopoiesis.

Stem cell mobilization

Release of hematopoietic stem cells into the periphery of patients in response to chemotherapy or cytokine stimulation was first documented in the late 1970s and early 1980s [15]. This process, termed mobilization, has been shown to be induced clinically or experimentally in animal models by a wide number of molecules: cytokines such as G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-7, IL-3, IL-12, stem cell factor (SCF), and flt-3 ligand; chemokines like IL-8, Mip-1 α , Gro β , or SDF-1; and the chemotherapeutic agents cyclophosphamide (Cy) and paclitaxel. These molecules differ in their time frame to achieve mobilization, the type of cells mobilized, and efficiency. G-CSF is the most commonly used agent, usually administered daily at a dose of 5–10 μ g/kg for 5–10 days, sometimes in combination with cyclophosphamide [15]. However, some patients, and also a minority of healthy individuals, are poor mobilizers [10].

Human stem cell mobilization and positive selection of immature CD34⁺ cells have become the preferred source of repopulating stem cells for clinical transplantation because of the higher cell yield of immature cells, shorter time frame needed to reach successful repopulation, and technical reduced intervention and pain advantages compared to harvested bone marrow cells [16]. However, the mechanism of stem cell mobilization is not fully understood. Mobilization of hematopoietic cells from the bone marrow into the circulation seems to be a multistep process in which adhesion interactions, which mediate anchorage of hematopoietic progenitors to the bone marrow stromal cells in response to stimulation with cytokines and chemokines, need to be disrupted [8]. Mobilized progenitor cells differ from their BM counterparts by several features. A significantly higher percentage of mobilized CD34⁺ cells are noncycling quiescent cells [17,18]. Recent results with enriched human CD34⁺ cells from G-CSF-mobilized peripheral blood leukocytes (PBL) compared to bone marrow CD34⁺ cells from healthy

volunteers using cDNA array technology reveal that in addition to increased quiescence, the mobilized progenitors also express higher levels of proapoptotic genes such as caspases 3, 4, and 8 and lower levels of antiapoptotic genes such as antiproteinase 2, which may explain the sensitivity of mobilized progenitors to 5-fluorouracil (5-FU) despite their increased quiescent cell-cycle status [12,13]. Hematopoietic stem cell proliferation before emigration is believed to occur and play an important role in this process. G-CSF and Cy induces proliferation of hematopoietic cells within the bone marrow [19], since most mobilized CD34⁺ cells in the blood are quiescent [17,18]. It has been suggested that all BM cells enter cell cycle but that cells egress towards the blood only after the M phase by a process that may be related to cell-cycle status [20]. Combined stimulation with SCF and G-CSF leads to improved mobilization. In the murine system the addition of SCF induces higher levels of mobilization of long-term repopulating stem cells. In dog, baboon, and human transplantations, cells mobilized with G-CSF and SCF lead to faster recovery in transplanted recipients. These results suggest that a combination of cytokines such as SCF and G-CSF increase the levels of proliferation in the bone marrow prior to mobilization and could also increase the yield of long-term repopulating stem cells in clinical protocols [21]. Mobilized PBL cells are increasingly used clinically since the hematopoietic recovery in transplanted recipients (i.e., neutrophils and platelets) are much faster compared to patients transplanted with bone marrow cells. The more rapid engraftment is due to the increased cell dose of transplanted mobilized cells, in particular increased numbers of committed progenitor cells (including CD34⁺ cells, GM-CSF, and Mk-CFC). More importantly, there is evidence for qualitative differences between primitive, undifferentiated human progenitors obtained from mobilized PBL compared to bone marrow cells. The proliferation and differentiation potential of undifferentiated CD34⁺Lin⁻ or CD34⁺CD38⁻ cells from mobilized PBL is inferior to that of undifferentiated bone marrow cells. In addition, higher cell doses of mobilized cells are needed to highly repopulate immune-deficient NOD/SCID mice. Most importantly, mobilized CD34⁺ cells serially transplanted in preimmune sheep were also inferior to bone marrow cells [21]. These results should be carefully interpreted due to the surrogate xenogeneic limitations of these assays and the superior repopulation potential of mobilized cells in clinical protocols [22].

The expression of the very late antigen-4 (VLA-4) integrin and the cytokine receptor c-kit are also reduced on mobilized progenitor cells, while the levels of the metalloproteinase (MMP) enzymes MMP-2 and MMP-9, which are needed for degradation of the extracellular matrix and for transendothelial migration, are increased [23,24]. Mechanistic insights into stem cell mobilization were provided by Papayannopoulou et al., using primate and murine animal models. This group demonstrated that VLA-4 plays a criti-

cal role in stem cell mobilization since anti-VLA-4 antibodies (Ab) induce mobilization of primate and murine stem/progenitor cells, which also involves signaling via the c-kit receptor [25]. Recently, Levesque et al. showed increased release of the proteolytic enzymes elastase and cathepsin G from murine BM neutrophils during Cy and G-CSF mobilization, reaching peak levels on days 4 and 5, correlating with stem cell egress [26]. These enzymes cleaved VCAM-1 from the bone marrow stromal cells, preventing VLA-4 antigens expressed on the surface of hematopoietic progenitors to bind to their ligand VCAM-1 expressed by stromal cells. Lastly, sulphated polysaccharides such as fucoidan induce increase of SDF-1 in the blood and concomitant murine and primate stem cell mobilization. This compound can still induce stem cell mobilization in double P and E selectin ligand knockout (KO) mice, suggesting that the mechanism is not only by preventing selectin interactions [27,28]. Taken together, these results demonstrate a major role for disrupting adhesion interactions between hematopoietic stem cells and the bone marrow stromal microenvironment during mobilization. These interactions involve integrins and selectins; however, there are additional players involved in stem cell mobilization (i.e., chemokines such as SDF-1 and IL-8, other cytokines such as SCF, and proteolytic enzymes such as the MMP superfamily).

SDF-1 and CXCR4 interactions

The essential roles of

SDF-1 and CXCR4 interactions in murine embryonic development and adult stem cell hematopoiesis

KO experiments revealed that murine embryos that lack the chemokine SDF-1 (also named CXCL-12) or its receptor CXCR4 have multiple defects that are lethal, including impaired bone marrow lymphoid and myeloid hematopoiesis [29–31]. However, while B lymphopoiesis in the fetal liver was also impaired due to the fact that this chemokine is a pre-B cell growth factor, T-cell development in the embryonic thymus and myeloid development in the fetal liver were not affected. These results demonstrate an essential role for this chemokine and its receptor in definitive fetal liver stem cell homing to the bone marrow and/or hematopoietic retention and repopulation of this organ during embryonic development. Unexpectedly, fetal liver cells isolated from CXCR4^{null} embryos can engraft the marrow of transplanted adult wild-type mice, preconditioned with total-body irradiation. However, stem cell self-renewal, retention of maturing hematopoietic cells within the bone marrow, and migration patterns of both myeloid and lymphoid progenitor cells, including thymic T-cell development, were defective [30,32,33]. While the levels of maturing myeloid and lymphoid cells in the bone marrow remained low even when a 10-fold increase of fetal liver cells was transplanted, the levels of immature CXCR4^{null} cells (i.e., c-kit⁺Sca-

$1^+Lin^{-/low}$ cells with a stem cell phenotype) were normal [34]. However, transplantation of CXCR4^{null} cells recovered from the bone marrow of these mice into serially transplanted secondary recipients resulted in additional reductions in the levels of engraftment compared to the levels obtained with serially transplanted wild-type cells. These results also demonstrate an essential role for SDF-1 and CXCR4 interactions in definitive stem cell repopulation and development in transplanted adult mice. Therefore, CXCR4^{null} progenitor cells recovered from the murine fetal liver do not qualify as hematopoietic stem cells. In addition to their inability to home and repopulate the bone marrow of the developing embryo, these cells also fail to give rise to high levels of multilineage myeloid and lymphoid cells in the bone marrow and peripheral blood of primary and serially transplanted secondary murine recipients, which is essential for a repopulating cell in order to qualify as a pluripotent stem cell with self-renewal potential. These results are of significance since transplantation of stem cells from the bone marrow of p21 KO mice required five consecutive serial transplantations in order to fully reveal defects in stem cell self-renewal and repopulation potential [35], while CXCR4^{null} serial transplantations revealed significant defects in engraftment potential already in the primary recipients, which were further intensified in secondary transplanted recipients! In addition, while CXCR4^{null} cells do not migrate to a gradient of SDF-1 in vitro in transwell assays, preliminary results from our experiments demonstrate SDF-1-mediated adhesion and migration in three-dimensional ECM-like gels of CXCR4^{null} cells, suggesting that these cells can partially compensate for the absence of CXCR4 [36]. Moreover, microparticles derived from activated platelets that express functional CXCR4 adhere to bone marrow endothelium-bound SDF-1, and also have the capacity to bind to murine stem cells and to immature human CD34⁺ cells via their platelet-binding sialo-mucin P-selectin (CD162) and integrin Mac-1 (CD11b–CD18) antigen. These interactions increase adhesion of human and murine progenitors to endothelium-bound SDF-1 and, more importantly, also increase in vivo murine stem cell homing and repopulation [37]. These results suggest that CXCR4⁺ platelets in the circulation of adult wild-type mice transplanted with CXCR4^{null} fetal liver cells could also increase homing and engraftment of CXCR4^{null} progenitor cells in response to SDF-1 signaling. Murine T cells that overexpress human CXCR4 and CD4 are mostly localized within the bone marrow of transgenic mice, demonstrating a central role for this chemokine in homing and retention of hematopoietic cells within the bone marrow microenvironment, most probably by chemotaxis, by activation of adhesion molecules, and also by influencing their cell-cycle status [38]. Mice reconstituted with progenitor cells infected with SDF-1 intrakine, preventing surface CXCR4 expression, suffered from impaired myeloid and lymphoid (both B- and T-cell) hematopoiesis, demonstrating a key role for this chemokine, as well, in release of maturing cells from the bone marrow into the circulation in adult hematopoiesis. Finally, trans-

plantation of infected murine progenitor cells that overexpress SDF-1 resulted in increased myeloid and B-lymphoid hematopoiesis while T-cell development was impaired, most probably due to the antiapoptotic survival properties of this chemokine [39–41]. A recent publication by Wright et al. demonstrated that purified adult murine hematopoietic stem cells migrate to SDF-1 and not to any other known chemokine revealing a central role for SDF-1/CXCR4 interactions in adult murine hematopoiesis [42]. Taken together, these results demonstrate essential roles for SDF-1 and CXCR4 interactions both in murine embryonic development and in steady-state, adult hematopoiesis (i.e., regulation of leukocyte trafficking and stem cell self-renewal). In addition, these results suggest that SDF-1 is a key regulator of murine stem cell migration, homing, and anchorage of repopulating cells to the bone marrow, as well as release of maturing cells into the blood circulation.

The roles of IL-8, SDF-1, and CXCR4 in stem cell mobilization and homing

Fibbe et al. have demonstrated that the CXC chemokine IL-8, which is a chemoattractant and activator of neutrophils, can rapidly induce stem cell mobilization in primates and in mice within a few hours; however, the total amounts of mobilized cells are low compared to mobilization induced by daily stimulations with G-CSF [43]. IL-8-induced mobilization involves activation of MMP-9 and the $\beta 2$ integrin LFA-1 (CD11a), since anti-MMP-9 or anti-LFA-1 antibodies significantly reduced mobilization [44]. LFA-1 expression is dynamic and bone marrow CD34⁺ stem cells can express LFA-1 within 24 hours [45]. In addition, neutralizing anti-LFA-1 Ab significantly reduced homing of murine progenitor cells to the host BM [46]. Alternatively, anti-LFA-1 treatment could also inhibit IL-8-induced mobilization indirectly via LFA-1-dependent activation of neutrophils. The role of MMP-9 in stem cell mobilization remains unclear, since results (also by Fibbe et al.) demonstrate normal IL-8-induced mobilization in MMP-9^{-/-} mice [47]. Other chemokines such as Gro β and MIP-1 α were also shown to induce modest mobilization of progenitors [48,49]. Aiuti et al. found very low levels of surface CXCR4 expression on mobilized human CD34⁺-enriched cells and reduced migration in vitro toward a gradient of SDF-1 in transwells [50]. We reported that while surface CXCR4 levels on freshly isolated human bone marrow or CB CD34⁺-enriched cells are fairly constant (about 40–50%), as is their migration toward SDF-1 in transwells (about 25%), the expression of CXCR4, and migration toward a gradient of this chemokine, are highly variable on mobilized CD34⁺-enriched cells obtained from G-CSF-treated healthy donors. These results strongly suggest involvement of SDF-1/CXCR4 interactions, as well, in mobilization of immature human CD34⁺ cells [51]. Efficient mobilization of murine stem/progenitor cells was observed following elevated levels of SDF-1 in the blood of immune-deficient SCID mice due to the injec-

tion of adenovirus expressing SDF-1 [52], or of met-SDF-1 [53]. Sweeney et al. reported a rapid increase in SDF-1 levels in the circulation of mice and primates treated with sulfated polysaccharides, followed by SDF-1-dependent mobilization of murine stem/progenitor cells [54]. In this report, a transient reversal of the SDF-1 gradient from the bone marrow into the circulation was rapidly formed. They demonstrate that fucoidan and Des X compete for SDF-1 binding to the bone marrow endothelium via its nonsignaling C terminus, leading to release of this chemokine into the circulation, followed by rapid mobilization of stem and progenitor cells. Interestingly, treatment with neutralizing anti-SDF-1 antibodies significantly reduced stem and progenitor cell mobilization in fucoidan-treated mice; however, the levels of mature leukocytes were not affected. These results reveal different sensitivities to the levels of SDF-1 between immature, undifferentiated cells and mature cells, demonstrating a higher dependence on this chemokine for cell migration among progenitor cells compared to mature white blood cells [54]. Finally, a correlation between lower levels of SDF-1 and CXCR4 expression in the periphery and higher mobilization rates of immature CD34⁺ cells in patients treated with Cy and G-CSF has been reported [55,56]. However, the mechanism, which regulates stem cell mobilization and the specific role of SDF-1/CXCR4 interactions in G-CSF-induced mobilization, are currently unclear.

Reduction of bone marrow SDF-1

levels and CXCR4 upregulation mediate

G-CSF-induced mobilization of human and murine stem cells

In recent reports proteolytic enzymes, including elastase, cathepsin G, MMP-2, and MMP-9, were found to inactivate SDF-1 by cleaving a few amino acids at the signaling N-terminus of this chemokine, creating a truncated chemokine that is devoid of chemotaxis [57,58]. Preliminary results by Levesque and Simmons et al. demonstrate that in addition to cleavage of VCAM-1 in the murine BM by elastase and cathepsin G during G-CSF- and Cy-induced mobilization, these enzymes also inactivate and degrade SDF-1 in the murine bone marrow in a gradual manner, as part of the mobilization process [26,60]. In parallel, results from our experiments demonstrate that G-CSF induces gradual proteolytic degradation of human and murine bone marrow SDF-1 via elastase, accompanied by a gradual increase in CXCR4 expression on bone marrow cells [61–63]. In parallel, the levels of this chemokine and its receptor in the circulation were less affected. Unexpectedly, G-CSF increased SDF-1 mRNA expression by osteoblasts, leading to transient elevations of bone marrow SDF-1 levels and transient decreases of CXCR4 expression after each stimulation [63]. Most importantly, inhibition of neutrophil elastase *in vivo* in BALB/c mice stimulated with G-CSF led to reduction of SDF-1 degradation in the murine bone marrow and also prevented mobilization of both mature and immature progenitor cells, demonstrating an essential role for elastase in optimal stem

cell mobilization [63]. Of interest, two defective forms of the human elastase gene due to genetic mutations are the cause of two infantile neutropenias, i.e., severe congenital neutropenia and cyclic hematopoiesis (also known as Kostman disease), suggesting a role for elastase-induced degradation of SDF-1, adhesion molecules, and ECM components, also in the constitutive homeostatic release of maturing hematopoietic cells into the human blood circulation [64]. Of interest, neutralizing anti-CXCR4 or anti-SDF-1 antibodies significantly reduced stem cell mobilization, demonstrating a role for SDF-1/CXCR4 signaling in cell egress as well [63]. It appears that although a dramatic reduction of SDF-1 levels within the bone marrow is needed for stem cell mobilization, concentrations of this chemokine are still higher in the bone marrow than in the circulation. Our data are not in disagreement with a mechanism of egress involving SDF-1 signaling, since it has been reported that hematopoietic T cells can migrate in a SDF-1-dependent manner without the formation of a gradient when the chemokine is presented by fibronectin [65] or by human endothelial cells under shear flow [66]. The ability of human SDF-1 to mediate transendothelial migration could also explain the inhibition of murine and human mobilization in our experiments by neutralizing anti-CXCR4 and anti-SDF-1 antibodies. Moreover, human T cells are also able to migrate away from a gradient of SDF-1 [67].

Lastly, results obtained by the groups of Rafii and Moore et al. reveal that SDF-1-, G-CSF-, and VEGF-mediated mobilization in mice is dependent on activation of MMP-2 and MMP-9. Treatment of mice with the MMP inhibitor MPI prevented both murine stem cell mobilization as well as homing to the bone marrow [68]. Additional results by this group show that MMP-9 causes the release of SCF from the bone marrow to the circulation, which is essential for SDF-1, and G-CSF-mediated mobilization in mice [69]. Figure 1 illustrates a model for G-CSF-induced mobilization.

SDF-1 and

CXCR4 interactions mediate

immature human cell homing and

repopulation in transplanted NOD/SCID and

B2m^{null} NOD/SCID mice: relevance for clinical

autologous and allogeneic CD34⁺-enriched cell transplantation

Human and murine SDF-1 are cross-reactive and differ in one amino acid, enabling human CXCR4 to respond to murine SDF-1 signaling and vice versa. We demonstrated that SDF-1/CXCR4 interactions tightly regulate homing and repopulation of human SCID repopulating cells (SRC)/stem cells from BM, CB, and mobilized CD34⁺-enriched cells by chemotaxis and activation of the major integrins LFA-1, VLA-4, and VLA-5 under shear flow [51,70,71]. The importance of these adhesion molecules in homing of both human and murine progenitor cells has been demonstrated by the use of neutralizing antibodies [46,71]. Short-term 24- to 48-hour prestimulation of human CD34⁺-enriched cells




Figure 1. A model for stem cell mobilization by G-CSF. In steady state (upper panel), stem cells are localized in close proximity to stromal cells. Retention is mediated by adhesion molecules such as VCAM-1/VLA-4 and through SDF-1/CXCR4 interactions. During mobilization (lower panel), G-CSF induces both cell proliferation and release of neutrophil proteases (elastase, cathepsin G, and MMPs), which participate in cell egress by degrading retention signals (VCAM-1 and SDF-1) and by remodeling the extracellular matrix. Upregulation of CXCR4 on BM cells during G-CSF-induced mobilization suggests active participation of SDF-1/CXCR4 interactions in the migration of cells towards the blood.

with SCF and IL-6 in vitro before transplantation increases surface CXCR4 expression and in vitro migration towards a gradient of SDF-1, as well as in vivo homing and repopulation in transplanted NOD/SCID mice and serially transplanted B2m^{null} NOD/SCID mice. In summary, we have recharacterized human SRC/stem cells as CD38^{-low}/CXCR4⁺ cells with the potential to home and repopulate the bone marrow of transplanted NOD/SCID mice and serially transplanted B2m^{null} NOD/SCID mice with high levels of both myeloid and lymphoid cells while maintaining undifferentiated cells, in response to stimulation with SDF-1. Interestingly, a recent report demonstrated equal levels of NOD/SCID engraftment by CB CD34⁺/CD38⁻/CXCR4⁻ and CXCR4⁺ sorted cells with neutralizing anti-CXCR4 Ab. These engraftment levels, however, are very low compared to the entire sorted CB CD34⁺/CD38⁻ cell population [72,73]. More importantly, preliminary results from our studies demonstrate that sorted

CB CD34⁺/CXCR4⁻ cells harbor functional intracellular CXCR4, which can rapidly be expressed on the cell surface within 24 hours, and rescue low SDF-1-dependent engraftment in transplanted NOD/SCID mice. Both homing to the murine bone marrow and repopulation of transplanted NOD/SCID mice by sorted CB CD34⁺/CXCR4⁻ cells and the entire CD34⁺-enriched cell population were blocked by co-injection with neutralizing anti-CXCR4 Ab [74]. Recent results with enriched human CD34⁺ progenitor cells demonstrated that the more differentiated CD38⁺ cells also secrete low levels of SDF-1 in an autocrine manner [75–77]. These results could explain the reduced surface CXCR4 expression, reduced in vitro migration toward a gradient of SDF-1, and reduced in vivo homing and repopulation potential in transplanted NOD/SCID mice by the more mature CD34⁺/CD38⁺ cells [51,71,78]. Autocrine secretion of SDF-1 could interfere with exogenous BM SDF-1 signals and reduce its chemotactic/homing potential, as compared to primitive CD34⁺/CD38^{-low} cells within the CD34⁺ population, since the more primitive cells do not secrete this chemokine [75,76]. In other reports, Eaves et al. demonstrated that high doses of this chemokine induce quiescence of undifferentiated human CD34⁺ cells including LTC-IC and CRU stem cells and that short stimulation in vitro with low levels of this chemokine increase NOD/SCID repopulation potential of human cord blood CD34⁺ enriched cells previously stimulated with other cytokines [77,79]. Stem and progenitor cell niches are mostly localized along the endosteum region in proximity to immature bone-forming osteoblasts and also in periarterial sites [80,81]. The highest levels of SDF-1 production in adult human bone marrow were detected along the endosteum region, secreted by immature osteoblasts. In addition, this chemokine was highly expressed by both human and murine bone marrow endothelium [82,83]. Interestingly, Nilsson et al. demonstrated that primitive, undifferentiated murine stem cells preferentially home to the endosteum region while the more differentiated progenitors do not [84]. Furthermore, total-body irradiation and chemotherapy increased SDF-1 production that correlated with increased human stem cell repopulation of transplanted immune-deficient mice [83]. Higher SDF-1 levels may induce an improved SDF-1 gradient between the periphery and the bone marrow as well as have an increased antiapoptotic effect on repopulating stem cells leading to improved homing and repopulation in clinical protocols.

The relevance of SDF-1 and CXCR4 interactions in clinical human CD34⁺-enriched cell transplantation is currently being investigated. Preliminary results in autologous transplantation of positive CD34 selection after chemotherapy and G-CSF-induced mobilization show a correlation between the motility of the cells in vitro both in spontaneous and SDF-1-mediated migration and the rate of repopulation in patients [56]. These results are important since they demonstrate that homing and repopulation in transplanted patients are not random and that they correlate with the migra-

tion potential of the progenitor cells. In another report, allogeneic transplantation of CD34⁺-enriched cells in matched recipients demonstrated significantly faster platelet recovery in patients transplanted with immature CD34⁺ cells that express higher levels of CXCR4 as compared to those that received immature cells with lower levels of CXCR4 expression [85]. A growing number of manuscripts demonstrate decreased CXCR4 expression on mobilized human CD34⁺ cells compared to bone marrow CD34⁺ cells, which correlate with improved mobilization. These results suggest that manipulation of SDF-1/CXCR4 interactions could improve the outcome of stem cell mobilization for clinical transplantation [12,13,55,56]. At present, patients transplanted with allogeneic or autologous cells have low levels of primitive progenitor cells (about 10% of LTC-IC) and increased shortening of telomeres in different hematopoietic cells compared to healthy individuals. Therefore, improving the levels of stem cell homing and repopulation could also improve the success and cure rates of transplantation protocols [86]. Preliminary results with enriched CD34⁺ cell transplantation in patients [56,85] suggest that our approach of increased CXCR4 expression, migration towards a gradient of SDF-1, homing, and repopulation following short-term *ex vivo* stimulation with SCF and IL-6 could also improve the outcome of clinical stem cell transplantation.

Concluding remarks

Regulation of hematopoietic stem cell release, migration, and homing to the bone marrow, as well as the mechanism of different mobilization pathways, involve a complex interplay between adhesion molecules, chemokines, cytokines, proteolytic enzymes, stromal cells, and hematopoietic cells; however, the mechanism is not fully understood. In the current review we have discussed recent findings and have focused on the major roles of the chemokine SDF-1 and its receptor CXCR4 in stem cell mobilizations, including G-CSF and G-CSF with Cy-induced mobilization, as well as in stem cell homing to the bone marrow.

We suggest that SDF-1 and CXCR4 interactions are key players in stem cell homing to the bone marrow and anchorage (i.e., activation of adhesion interactions in order to retain stem cells within this organ). We also suggest that in addition to SDF-1 degradation and inactivation within the bone marrow by proteolytic enzymes such as neutrophil elastase, which is essential for optimal stem cell mobilization, interactions between this chemokine and its receptor are also needed for stem cell release and mobilization. For example, we suggest that IL-8, which is secreted in response to SDF-1 stimulation, and MMP-2 and MMP-9, which are mostly secreted by neutrophils but are also secreted by immature human CD34⁺ progenitor cells in response to stimulation with this chemokine, can also lead to migration away from the bone marrow across the endothelium into the circulation also in the absence of or against a gradient of SDF-

1 under shear flow forces within the extravascular space of the bone marrow [66]. Lastly, we suggest that in order to maintain stem cells in the circulation low levels of surface CXCR4 are required and may be achieved by factors in the blood plasma such as proteolytic enzymes that can also cleave CXCR4 in addition to SDF-1 [59]. Furthermore, increase in the levels of CXCR4 expression on the surface of stem cells in the circulation will mediate their homing and reengraftment of the bone marrow as part of homeostatic regulation of leukocyte trafficking as well as steady-state hematopoiesis and stem cell self-renewal, which go hand in hand with bone destruction and bone remodeling. However, this hypothesis is also an oversimplification of a much more complex and dynamic situation with physiological steady-state homeostatic as well as stress-induced mobilization situations in which the mechanisms and mode of regulation are still poorly understood.

A significant number of studies in the past few years have revealed insights into regulation of hematopoietic stem cell release, migration, and homing as well as the mechanism of different mobilization pathways. However, the exact sequence of events involving many different molecules is still not clear. More importantly, in addition to results from clinical mobilization protocols using Cy and G-CSF, which demonstrate a role for SDF-1 and CXCR4 interactions in immature human CD34⁺ cell mobilization, two recent reports also demonstrate a role for these interactions in autologous and allogeneic CD34⁺ cell homing and repopulation. Taken together, these results suggest that stem cell homing and release or mobilization are mirror images utilizing a similar mechanism and suggest manipulation of SDF-1/CXCR4 interactions in order to improve stem cell mobilization or to target migration of transplanted cells to specific organs. Furthermore, these results strongly support the idea that increasing the migration potential of immature human CD34⁺ cells prior to transplantation, either by short-term stimulation with SCF and IL-6 and/or by cotransplantation with accessory cells, could also increase homing and repopulation in transplanted patients, leading to improved treatment efficiencies and cure rates in clinical protocols.

References

1. Morrison S, Uchida N, Weissman IL (1995) The biology of hematopoietic stem cells. *Annu Rev Cell Dev Biol* 11:35
2. Medvinsky A, Dzierzak E (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* 86:897
3. Oostendorp RAJ, Harvey KN, Kusadasi N, et al. (2002) Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. *Blood* 99:1183
4. Medvinsky A, Dzierzak E (1999) Development of the hematopoietic stem cell: can we describe it? *Blood* 94:3613
5. Cumano A, Candido Ferraz J, Klaine M, Di Santo JP, Godin I (2001) Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. *Immunity* 15:477
6. Yoder MC, Hiatt K (1997) Engraftment of embryonic hematopoietic cells in conditioned newborn recipients. *Blood* 89:2176

7. Broxmeyer HE (1996) Primitive hematopoietic stem and progenitor cells in human umbilical cord blood: an alternative source of transplantable cells. *Cancer Treat Res* 84:139
8. Papayannopoulou T (2000) Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. *Semin Hematol* 37:11
9. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL (2001) Physiological migration of hematopoietic stem and progenitor cells. *Science* 294:1933
10. Fu S, Liesveld J (2000) Mobilization of hematopoietic stem cells. *Blood Rev* 14:205
11. Vaday GG, Lider O (2000) Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. *J Leukoc Biol* 67:149
12. Steidl U, Kronenwett R, Rohr U-P, et al. (2002) Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34⁺ hematopoietic stem cells. *Blood* 99:2037
13. Graf L, Heimfeld S, Torok-Storb B (2001) Comparison of gene expression in CD34⁺ cells from bone marrow and G-CSF-mobilized peripheral blood by high-density oligonucleotide array analysis. *Biol Blood Marrow Transpl* 7:486
14. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque J-P (1998) Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. *Blood* 92:3465
15. To LB, Haylock DN, Simmons PJ, Juttner CA (1997) The biology and clinical uses of blood stem cells. *Blood* 89:2233
16. Link DC (2000) Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. *Semin Hematol* 37:25
17. Roberts AW, Metcalf D (1995) Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. *Blood* 86:1600
18. Uchida N, He D, Frieria AM, et al. (1997) The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. *Blood* 89:465
19. Morrison SJ, Wright DE, Weissman IL (1997) Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. *Proc Natl Acad Sci U S A* 94:1908
20. Wright DE, Cheshier SH, Wagers AJ, Randall TD, Christensen JL, Weissman IL (2001) Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. *Blood* 97:2278
21. Verfaillie CM (2002) Hematopoietic stem cells for transplantation. *Nature Immunology* 3:314
22. Korbling M, Anderlini P (2001) Peripheral blood stem cell vs bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood* 98:2900
23. Mohle R, Haas R, Hunstein W (1993) Expression of adhesion molecules and c-kit on CD34⁺ hematopoietic progenitor cells: comparison of cytokine mobilized blood stem cells with normal bone marrow and peripheral blood. *J Hematother* 3:483
24. Pruijt JFM, Fibbe WE, Laterveer L, et al. (1999) Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). *Proc Natl Acad Sci U S A* 96:10863
25. Papayannopoulou T, Nakamoto B (1993) Peripheralization of hematopoietic progenitors in primates treated with anti-VLA4 integrin. *Proc Natl Acad Sci U S A* 90:9374
26. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ (2001) Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. *Blood* 98:1289
27. Frenette PS, Weiss L (2000) Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: evidence for selectin-dependent and independent mechanisms. *Blood* 96:2460
28. Sweeney EA, Priestley GV, Nakamoto B, Collins RG, Beaudet AL, Papayannopoulou T (2000) Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. *Proc Natl Acad Sci U S A* 97:6544
29. Nagasawa T, Hirota S, Tachibana K, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 382:635
30. Ma Q, Jones D, Springer TA (1999) The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. *Immunity* 10:463
31. Zou YR, Kottman AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 393:595
32. Hargreaves DC, Hyman PL, Lu TT, et al. (2001) A coordinated change in chemokine responsiveness guides plasma cell movements. *J Exp Med* 194:45
33. Egawa T, Kawabata K, Kawamoto H, et al. (2001) The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. *Immunity* 15:323
34. Kawabata K, Ujikawa M, Egawa T, et al. (1999) A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. *Proc Natl Acad Sci U S A* 96:5663
35. Cheng T, Rodrigues N, Shen H, et al. (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 287:1804
36. Kollet O, Grabovsky V, Franitza S, Lider O, Alon R, Lapidot T (2000) SDF-1 induces survival, adhesion, and migration in 3D ECM-like gels of murine CXCR4^{null} fetal liver cells via another GPCR. *Blood* 96:65a
37. Janowska-Wieczorek A, Majka M, Kijowski J, et al. (2001) Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. *Blood* 98:3143
38. Sawada S, Gowrishankar K, Kitamura R, Suzuki M, Tahara S, Koito A (1998) Disturbed CD4⁺ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. *J Exp Med* 187:1439
39. Broxmeyer HE, Hangoc G, Cooper S, Kim CH (1999) Enhanced myelopoiesis in SDF-1-transgenic mice: SDF-1 modulates myelopoiesis by regulating progenitor cell survival and inhibitory effects of myelo-suppressive chemokines. *Blood* 94:650a
40. Onai N, Zhang Y, Yoneyama H, Kitamura T, Ishikawa S, Matsushima K (2000) Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. *Blood* 96:2074
41. Lee Y, Gotoh A, Kwon H-J, et al. (2002) Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. *Blood* 99:4307
42. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL (2002) Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. *J Exp Med* 195:1145
43. Laterveer L, Lindley IJ, Hamilton MS, Willemze R, Fibbe WE (1995) Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. *Blood* 85:2269
44. Fibbe WE, Pruijt JF, van Kooyk Y, Figdor CG, Opendakker G, Willemze R (2000) The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem cell mobilization. *Semin Hematol* 37:19
45. Torensma R, Raymakers RA, van Kooyk Y, Figdor CG (1996) Induction of LFA-1 on pluripotent CD34⁺ bone marrow cells does not affect lineage commitment. *Blood* 87:4120
46. Asaumi N, Omoto E, Mahmut N, et al. (2001) Very late antigen-5 and leukocyte function-associated antigen-1 are critical for early stage hematopoietic progenitor cell homing. *Ann Hematol* 80:387
47. de Kruijf E-VFM, van Os R, van Schie M, et al. (2001) IL-8 induced hematopoietic progenitor cell mobilization in mice coincides with

- MMP-9 (gelatinase-B) release from neutrophils and is not reduced in MMP-9 deficient mice. *Blood* 98:83a
48. King AG, Horowitz D, Dillon SB, et al. (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRO β . *Blood* 97:1534
 49. Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. *Stem Cells* 18:320
 50. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC (1997) The chemokine SDF-1 is a chemoattractant for human CD34⁺ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34⁺ progenitors to the peripheral blood. *J Exp Med* 185:111
 51. Peled A, Petit I, Kollet O, et al. (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 283:845
 52. Hattori K, Heissig B, Tashiro K, et al. (2001) Plasma elevation of stromal-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. *Blood* 97:3354
 53. Shen H, Cheng T, Olszak I, et al. (2001) CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. *J Immunol* 166:5027
 54. Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayanopoulou T (2002) Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. *Blood* 99:44
 55. Gazitt Y, Liu Q (2001) Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34⁺ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. *Stem Cells* 19:37
 56. Voermans C, Kooi ML, Rodenhuis S, van der Lelie H, van der Schoot CE, Gerritsen WR (2001) In vitro migratory capacity of CD34⁺ cells is related to hematopoietic recovery after autologous stem cell transplantation. *Blood* 97:799
 57. Delgado M, Clark-Lewis I, Loetscher P, et al. (2001) Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. *Eur J Immunol* 31:699
 58. McQuibban GA, Butler GS, Gong J-H, et al. (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor 1. *J Biol Chem* 276:43503
 59. Valenzuela-Fernandez A, Planchenault T, Baleux F, et al. (2002) Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. *J Biol Chem* 277:15677
 60. Levesque J-P, Bendall LJ, Hendy J, Williams B, Simmons PJ (2001) SDF-1 α is inactivated by proteolytic cleavage in the bone marrow of mice mobilized by either G-CSF or cyclophosphamide. *Blood* 98:831a
 61. Lapidot T, Szyper-Kravitz M, Peled A, et al. (1999) A single dose of human G-CSF inhibited production of SDF-1 in the bone marrow and upregulated CXCR4 expression on immature and mature hematopoietic cells prior to their mobilization. *Blood* 94:606a [abstract]
 62. Petit I, Szyper-Kravitz M, Nagler A, et al. (2001) Involvement of SDF-1/CXCR4 interactions in G-CSF induced mobilization of human and murine stem/progenitor cells. *Blood* 98:811a [abstract]
 63. Petit I, Szyper-Kravitz M, Nagler A, et al. (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4. *Nature Immunology* 3:687
 64. Dale DC, Person RE, Bolyard AA, et al. (2000) Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. *Blood* 96:2317
 65. Pelletier AJ, van der Laan LJ, Hildbrand P, et al. (2000) Presentation of chemokine SDF-1 α by fibronectin mediates directed migration of T cells. *Blood* 96:2682
 66. Cinamon G, Shinder V, Alon R (2001) Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. *Nature Immunology* 2:515
 67. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT (2000) Active movement of T cells away from a chemokine. *Nat Med* 6:543
 68. Heissig B, Hattori K, Dias S, et al. (2000) In vivo inhibition of metalloproteinases blocks chemo-cytokine induced endothelial and hematopoietic stem cell mobilization. *Blood* 96:540a
 69. Heissig B, Hattori K, Dias S, et al. (2002) Matrix recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell* 109:625
 70. Peled A, Kollet O, Ponomaryov T, et al. (2000) The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34⁺ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. *Blood* 95:3289
 71. Kollet O, Spiegel A, Peled A, et al. (2001) Exclusive homing of human CD38⁻/low CXCR4⁺ stem cells to the spleen and bone marrow of immune deficient mice within 1–6 hours. *Blood* 97:3283
 72. Rosu-Myles M, Gallacher L, Murdoch B, et al. (2000) The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. *Proc Natl Acad Sci U S A* 97:14626
 73. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc Natl Acad Sci U S A* 94:5320
 74. Kollet O, Petit I, Kahn J, et al. (2002) Sorted human cord blood CD34⁺/CXCR4⁻ cells contain internal CXCR4 which can oscillate in vivo and rescue low SDF-1 dependent repopulation in NOD/SCID mice. *Blood* (in press)
 75. Aiuti A, Turchetto L, Cota M, et al. (1999) Human CD34⁺ cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. *Blood* 94:62
 76. Lataillade JJ, Clay D, Bourin P, et al. (2002) Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34⁺ cells: evidence for an autocrine/paracrine mechanism. *Blood* 99:1117
 77. Cashman L, Clark-Lewis I, Eaves A, Eaves C (2002) Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. *Blood* 99:792
 78. Viardot A, Kronenwett R, Deichmann M, Haas R (1998) The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34⁺ hematopoietic stem cells. *Ann Hematol* 77:193
 79. Glimm H, Tang P, Clark-Lewis I, von Kalle C, Eaves C (2002) Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice. *Blood* 99:3454
 80. Lambertsen RH, Weiss L (1984) A model of intramedullary hematopoietic microenvironments based on stereologic study of the distribution of endocloned marrow colonies. *Blood* 63:287
 81. Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, Becker PS (1998) Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. *J Histochem Cytochem* 46:371
 82. Imai K, Kobayashi M, Wang J, et al. (1999) Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. *Blood* 93:149
 83. Ponomaryov T, Peled A, Petit I, et al. (2000) Increased expression of the chemokine SDF-1 following DNA damage: relevance for human stem cell function. *J Clin Invest* 106:1331
 84. Nilsson SK, Johnston HM, Coverdale JA (2001) Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. *Blood* 97:2293
 85. Spencer A, Jackson J, Baulch-Brown C (2001) Enumeration of bone marrow "homing" haemopoietic stem cells from G-CSF-mobilized normal donors and influence on engraftment following allogeneic transplantation. *Bone Marrow Transplant* 28:1019
 86. Podesta M (2001) Transplantation hematopoiesis. *Curr Opin Hematol* 8:331